BioTuesdays

Roth starts Zafgen at buy; PT $8

Roth Capital Partners launched coverage of Zafgen (NASDAQ:ZFGN) with a “buy” rating and price target of $8. The stock closed at $2.56 on April 25.

Zafgen has recently had a two major set-backs: a clinical hold placed on its lead asset, ZGN-1061, for the treatment of Type 2 diabetes on Nov. 26, 2018 and suspension of its IND filing for ZGN-1258 on March 11, 2019 for Prader-Willi syndrome based on an unexpected finding in muscle tissue in long-term rodent toxicology studies, writes analyst Yasmeen Rahimi.

“We have a high conviction that Zafgen can clear both hurdles with strong execution in the upcoming months,” she said. “Thus, we believe there will be a recovery in Zafgen shares.”

The stock traded as high as $12.35 last September.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.